KYV-101 is under clinical development by Kyverna Therapeutics and currently in Phase II for Primary Progressive Multiple Sclerosis (PPMS). According to GlobalData, Phase II drugs for Primary Progressive Multiple Sclerosis (PPMS) have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how KYV-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

KYV-101 overview

KYV-101 is under development for the treatment of refractory myasthenia gravis, relapsed or refractory lupus nephritis, diffuse cutaneous systemic sclerosis (scleroderma), primary and secondary progressive multiple sclerosis, idiopathic necrotizing myopathy (INM) consisting of dermatomyositis (DM), necrotizing myopathy, anti-HMGCoA-associated myopathy, and polymyositis (PM), systemic lupus erythematosus (SLE) with nephritis, and ANCA-associated vasculitis (AAV). The therapeutic candidate is an autologous CAR-T cell therapy which acts by targeting B cell antigen CD-19. It is administered through intravenous route.

Kyverna Therapeutics overview

Kyverna Therapeutics (Kyverna) is a cell therapy company that is into advancing treatment options for addressing the unmet medical needs for inflammatory and autoimmune diseases. The company utilizes synReg-T cell (synthetic regulatory T cells) platform technology which facilitates engineering and genetic reprogramming of synReg-T cells to suppress autoimmune diseases and synNotch CAR-T platform, a synthetic gene expression system that enables the development of synNotch CAR-T cells (chimeric antigen receptor T cells) against autoimmune diseases. It is investigating engineered T cell therapies to treat lupus nephritis, systemic sclerosis and inflammatory bowel disease (IBD) through SmarTcell, a genetic engineering toolbox. The company’s key funding partners include Vida Ventures, Westlake Village BioPartners, and Gilead Sciences Inc. Kyverna is headquartered in Emeryville, California, the US.

For a complete picture of KYV-101’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.